Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson's disease.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30385548.
- Also identified by DOI 10.1126/science.aat8407 and PMC identifier 6431793.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The pathologic accumulation and aggregation of α-synuclein (α-syn) underlies Parkinson's disease (PD). The molecular mechanisms by which pathologic α-syn causes neurodegeneration in PD are not known. Here, we found that pathologic α-syn activates poly(adenosine 5'-diphosphate-ribose) (PAR) polymerase-1 (PARP-1), and PAR generation accelerates the formation of pathologic α-syn, resulting in cell death via parthanatos. PARP inhibitors or genetic deletion of PARP-1 prevented pathologic α-syn toxicity. In a feed-forward loop, PAR converted pathologic α-syn to a more toxic strain. PAR levels were increased in the cerebrospinal fluid and brains of patients with PD, suggesting that PARP activation plays a role in PD pathogenesis. Thus, strategies aimed at inhibiting PARP-1 activation could hold promise as a disease-modifying therapy to prevent the loss of dopamine neurons in PD.
Medical subject headings
- Parkinson Disease
- Poly (ADP-Ribose) Polymerase-1
- Poly Adenosine Diphosphate Ribose
- alpha-Synuclein